Evolution of epitope-specific IgE and IgG₄ antibodies in children enrolled in the LEAP trial.

ABSTRACT:

Background

In the LEAP (Learning Early About Peanut Allergy) trial, early consumption of peanut in high-risk infants was found to decrease the rate of peanut allergy at 5 years of age. Sequential epitope-specific (ses-)IgE is a promising biomarker of clinical peanut reactivity.

Objective

We sought to compare the evolution of ses-IgE and ses-IgG₄ in children who developed (or not) peanut allergy and to evaluate the immunomodulatory effects of early peanut consumption on these antibodies.

Methods

Sera from 341 children (LEAP cohort) were assayed at baseline, 1, 2.5, and 5 years of age, with allergy status determined by oral food challenge at 5 years. A bead-based epitope assay was used to quantitate ses-IgE and ses-IgG₄ to 64 sequential epitopes fr

SUBMITTER: Suarez-Farinas M 

PROVIDER: S-EPMC8480440 | biostudies-literature | 2021 Sep

REPOSITORIES: biostudies-literature